{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:55:03Z","timestamp":1793174103294,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.autrev.2009.10.003","type":"journal-article","created":{"date-parts":[[2009,10,24]],"date-time":"2009-10-24T08:50:33Z","timestamp":1256374233000},"page":"188-193","source":"Crossref","is-referenced-by-count":277,"title":["Autoimmune diseases induced by biological agents"],"prefix":"10.1016","volume":"9","author":[{"given":"Manuel","family":"Ramos-Casals","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Roberto-Perez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candido","family":"Diaz-Lagares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jose","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther A.","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2009.10.003_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2009.10.003_bib2","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2009.10.003_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","article-title":"A systematic review of the off-label use of biological therapies in systemic autoimmune diseases","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2009.10.003_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","article-title":"Vasculitis induced by tumor necrosis factor-targeted therapies","volume":"10","author":"Ramos-Casals","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2009.10.003_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep080","article-title":"Anti-TNF-induced lupus","volume":"48","author":"Williams","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2009.10.003_bib7","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2009.10.003_bib8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/BOR.0b013e3282f1331f","article-title":"Drug-induced vasculitis","volume":"20","author":"Wiik","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/kep046","article-title":"Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases","volume":"48","author":"Da\u00efen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2009.10.003_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/ard.2003.018093","article-title":"Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies","volume":"63","author":"Jonsdottir","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.61.4.358","article-title":"Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections","volume":"61","author":"Ferraccioli","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib13","first-page":"351","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"35","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2009.10.003_bib14","first-page":"2446","article-title":"The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event","volume":"34","author":"Sebastian","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib15","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2009.10.003_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2009.10.003_bib17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"St\u00fcbgen","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2009.10.003_bib18","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-007-0657-3","article-title":"Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis","volume":"26","author":"Kotyla","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","article-title":"Guillain\u2013Barr\u00e9 and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2009.10.003_bib20","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.080791","article-title":"Postmarketing surveillance of the safety and effectiveness of etanercept in Japan","volume":"36","author":"Koike","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2009.10.003_bib23","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2009.10.003_bib24","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Behcet's disease\u2014review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2009.10.003_bib25","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2009.10.003_bib26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/art.23440","article-title":"Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al.","volume":"58","author":"Scrivo","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2009.10.003_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib28","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1365-2133.2008.09019.x","article-title":"Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome","volume":"160","author":"Driessen","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2009.10.003_bib30","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/j.1365-2133.2008.08470.x","article-title":"New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra","volume":"158","author":"Gonz\u00e1lez-L\u00f3pez","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib31","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2007.080929","article-title":"Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma","volume":"67","author":"Mielke","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gut.2007.138305","article-title":"Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease","volume":"57","author":"El Fassi","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2009.10.003_bib33","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ibd.20215","article-title":"Exacerbation of ulcerative colitis after rituximab salvage therapy","volume":"13","author":"Goetz","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib34","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1463-1318.2008.01490.x","article-title":"Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept)","volume":"10","author":"Yazisiz","year":"2008","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.autrev.2009.10.003_bib35","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib36","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2133.2007.08009.x","article-title":"Development of Crohn disease in a patient on etanercept for psoriasis","volume":"157","author":"Ahmad","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib37","first-page":"752","article-title":"Development of Crohn's disease in a patient taking etanercept","volume":"32","author":"Oh","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2009.10.003_bib38","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3899\/jrheum.080399","article-title":"New onset of inflammatory polyarthritis in a patient taking adalimumab","volume":"36","author":"Lee","year":"2009","journal-title":"J Rheumatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997209001724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997209001724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T08:04:08Z","timestamp":1710662648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997209001724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1568997209001724"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2009.10.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}